Teneobio Inc.

Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from  Galapagos, Sarepta, Amgen, LianBio and X4

Plus: Harpoon sinks as AbbVie declines option, and China companies Cure Genetics, Frametact in gene therapy deal

A deal with Kite offers Arcellx manufacturing capability and global commercial potential

Roche to pay $250M for Good Therapeutics’ PD-1-regulated IL-2 program, leaving new company Bonum Therapeutics to develop the platform

Amgen reports 23% ORR, 13.2 months OS for DLL3-targeted T cell engager in small cell lung cancer

With patent expirations ahead, deal gives Amgen immunology asset approved for vasculitis indication, with potential for label expansions

AZ’s takeout of a single-asset spinout for $100M up front is but the latest payout to shareholders in TeneoBio

Pharma adds bispecific with purchase of TeneoTwo, bringing more returns to shareholders, including Lightspeed and Sutter Hill

Hybrid firm’s ‘leap’ backing Stanford spinout spurred more life sciences deals, with onetime Abingworth partner building team and portfolio

Plus Arnay partners with Alloy and updates from DBV and more